TECHNOLOGY

• Point.1

  Three Corneal Transplant Supply Limitations; More than 10 Million Patients Waiting Worldwide

  First, donor corneas are required; second, corneal transplants are not easy for general practitioners to perform and require the skill of experienced doctors; and third, eye banks are a necessary social infrastructure to ensure the safe and equitable delivery of donor corneas to patients. Because there are few countries or regions in the world where all of these conditions are met, there are more than 10 million patients on the waiting list for corneal transplants worldwide.

  Conventional Corneal Transplantation Treatment

  

  Cellusion's Proposed Solutions

  
• Point.2

  Cellusion's Innovative Approach to Solving the Three Supply Limitations

  The technologies and products that Cellusion is developing can solve the bottlenecks in corneal transplants. First, it is possible to mass-produce CECSi cells, corneal endothelial cell substitute from iPSC, which function in the same way as corneal endothelial cells. The second method of treatment using CECSi cells is called cell injection therapy, in which a suspension of CECSi cells is transplanted into the eye using a syringe. As the procedure is less invasive and less stressful for the patient, ophthalmologists can learn the surgical technique in a short amount of time, leading to the procedure being widely accepted by ophthalmologists. Thirdly, unlike donor-dependent therapies, the products we are developing are based on the same allogeneic iPSC cell stock, meaning that they can always be delivered to patients in the same way as ordinary pharmaceuticals, even without an eye bank.